3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
15
Withdrawn
3
Unknown
1
Terminated
1
Recruiting
1
No longer available
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Breast Neoplasms
1
Interventions
Specimen Handling
334
Magnetic Resonance Spectroscopy
334
Radiotherapy
316
Cyclophosphamide
296
pembrolizumab
281
Cisplatin
269
Carboplatin
246
Drug Therapy
238
Blood Specimen Collection
233
Biopsy
204
Bevacizumab
185
Gemcitabine
181
venetoclax
172
Radiosurgery
172
Oxaliplatin
164
Capecitabine
164
fludarabine
161
Paclitaxel
158
Nivolumab
158
Standard of Care
136
Surveys and Questionnaires
131
Surgical Procedures, Operative
130
Dexamethasone
126
Fluorouracil
124
Docetaxel
113
Rituximab
112
tislelizumab
110
Cytarabine
104
Azacitidine
101
Radiation
100
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
OTHER
×
veliparib
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled